TET2 anticorps (Internal Region)
-
- Antigène Voir toutes TET2 Anticorps
- TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))
-
Épitope
- Internal Region
- Reactivité
- Humain, Souris, Chien
-
Hôte
- Chèvre
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp TET2 est non-conjugé
-
Application
- Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)
- Séquence
- C-PHPQSNNDQQ REGSF
- Specificité
- This antibody is expected to recognize both reported isoforms (NP_001120680.1 and NP_060098.3).
- Réactivité croisée (Details)
-
Species reactivity (expected):Mouse and Canine (Dog).
Species reactivity (tested):Human. - Purification
- Ammonium Sulphate Precipitation followed by antigen Affinity Chromatography using the immunizing peptide
- Immunogène
- Peptide with sequence from the internal region of the protein sequence according to NP_001120680.1 and NP_060098.3. Genename: TET2
- Top Product
- Discover our top product TET2 Anticorps primaire
-
-
- Indications d'application
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Concentration
- 0.5 mg/mL
- Buffer
- Tris saline, pH ~7.3 with 0.02 % Sodium Azide and 0.5 % BSA
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
- Avoid repeated freezing and thawing.
- Stock
- 4 °C/-20 °C
- Stockage commentaire
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
- Antigène
- TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))
- Autre désignation
- TET2 (TET2 Produits)
- Synonymes
- anticorps KIAA1546, anticorps MDS, anticorps Ayu17-449, anticorps E130014J05Rik, anticorps mKIAA1546, anticorps RGD1311625, anticorps tet methylcytosine dioxygenase 2, anticorps TET2, anticorps Tet2
- Sujet
- TET2 is frequently mutated in myelodysplastic syndromes, a heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. It Catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is Broadly expressed. Highly expressed in hematopoietic cells, highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes.Synonyms: KIAA1546, Methylcytosine dioxygenase TET2
- ID gène
- 54790
- NCBI Accession
- NP_001120680
- UniProt
- Q6N021
- Pathways
- L'effet Warburg
-